As drug development pushes into more complex antibody formats, the big question is: how do you really assess developability? In this episode, host Nimish Gera speaks with Shamit Shrivastava, Ph.D., founder and CEO of Apoha, to dive into Liquid Brain, his interdisciplinary innovation that’s changing the way researchers tackle developability of challenging antibody-based drugs. Shamit breaks down what makes Liquid Brain different from traditional developability methods, reveals how it’s unlocking new possibilities for complex format development, and shares a glimpse into Apoha’s future-including an exclusive preview of what’s coming at PEGS Europe this November.